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Abstract: Endothelial cell (EC) dysfunction is associated with many disease states including deep
vein thrombosis (DVT), chronic kidney disease, sepsis and diabetes. Loss of the glycocalyx, a thin
glycosaminoglycan (GAG)-rich layer on the EC surface, is a key feature of endothelial dysfunction
and increases exposure of EC adhesion molecules such as selectins, which are involved in platelet
binding to ECs. Once bound, platelets cause thrombus formation and an increased inflammatory
response. We have developed a GAG derived, selectin targeting anti-adhesive coating (termed
EC-SEAL) consisting of a dermatan sulfate backbone and multiple selectin-binding peptides designed
to bind to inflamed endothelium and prevent platelet binding to create a more quiescent endothelial
state. Multiple EC-SEAL variants were evaluated and the lead variant was found to preferentially
bind to selectin-expressing ECs and smooth muscle cells (SMCs) and inhibit platelet binding and
activation in a dose-dependent manner. In an in vivo model of DVT, treatment with the lead variant
resulted in reduced thrombus formation. These results indicate that EC-SEAL has promise as a
potential therapeutic in the treatment of endothelial dysfunction.
Keywords: glycocalyx; endothelial cell; dysfunction; selectin; dermatan sulfate; deep vein thrombosis
1. Introduction
Deep vein thrombosis (DVT) affects approximately 900,000 individuals annually in the United
States, and pulmonary emboli, a severe complication of DVT, are often observed in these patients [1].
Unlike in arterial thrombus, which is observed to initiate upon exposed extracellular matrix (ECM),
venous thrombus initiates from dysfunctional endothelium, in part due to platelet binding to
and activation on endothelium [1]. The binding and activation of platelets not only supports
thrombus formation, but also further contributes to the inflammatory state of the venous endothelium,
thus exacerbating the diseased vessel state [2].
Vascular endothelial cells (ECs) line the entire cardiovascular system in the human body. As the
innermost layer of the blood vessel lumen, ECs are in constant contact with the blood and perform
many critical functions. These include involvement in metabolism, regulating blood vessel tone,
permeability and growth, vascular smooth muscle cell (SMC) proliferation, inflammation, platelet and
leukocyte interactions, thrombosis and fibrinolysis [3–5]. Given these overlapping and wide-ranging
activities, it is not surprising that disruption of normal EC function is associated with many different
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disease states. Indeed, EC dysfunction has been shown to play a role in DVT, atherosclerosis,
myocardial infarction, peripheral vascular disease, stroke, hypertension, diabetes, chronic kidney
disease, infections including sepsis, and even cancer [3,4,6–11].
In general, characteristics of endothelial dysfunction include a reduction in ability of vessels to
vasodilate, along with increases in inflammation and prothrombotic properties [3,12]. Additionally,
loss of the glycocalyx, an anionic layer comprised primarily of glycosaminoglycans (GAGs) that lines
the endothelium, is a key feature of EC dysfunction [13,14]. The loss of this delicate layer causes
a significant increase in vascular wall permeability and subsequent migration of fluid, protein and
other cell types into the vessel [15]. Lack of a glycocalyx layer also results in exposure of EC adhesion
molecules such as E-selectin, P-selectin, intracellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1) and platelet-endothelial cell adhesion molecule 1 (PECAM-1) [13,16],
some of which are known to play a role in platelet binding to the endothelial cell surface. Once bound,
platelets release cytokines, chemokines and platelet activation factors, such as platelet activating factor
(PAF), neutrophil-activating peptide-2 (NAP-2) and platelet factor-4 (PF-4), which leads to thrombus
formation and a further increase in inflammatory cell recruitment to the site [17–20].
Endothelial dysfunction is likely a reversible disorder as eliminating cardiovascular risk factors
through such means as smoking cessation, hypertension control, cholesterol lowering and physical
activity have been shown to improve endothelial health [10]. Angiotensin converting enzyme (ACE)
inhibitors, N-acetylcysteine (NAC), ascorbic acid (Vitamin C), vitamin E, and erythropoietin (EPO)
have all been studied as potential therapeutics for EC dysfunction [21–24]. While some positive
outcomes have been observed, they have often displayed a minimal effect on overall endothelial health
or resulted in unintended cardiovascular events [4,23]. Therefore, additional means of targeting and
effectively treating EC dysfunction and reducing associated cardiovascular events are needed.
Targeting EC adhesion molecules, such as selectins, for therapeutic or diagnostic purposes
has been relatively well studied. Examples include microparticle drug delivery [25], therapeutic
gene delivery [26,27], inflammation reduction [28–30], cancer metastasis prevention [31] and in vivo
diagnostic imaging [32,33]. Specifically, antibodies and peptides have been utilized to target selectin
receptors on EC surfaces to prevent platelet and leukocyte binding and the subsequent inflammatory
response that occurs [28–30,34]. Therefore, our laboratory has recently developed several variants
of a GAG derived, selectin targeting anti-adhesive coating (termed EC-SEAL) designed to utilize
overexpressed selectins in EC dysfunction to prevent platelet binding and subsequent thrombus
formation and restore a more quiescent endothelial state. Each variant consists of a dermatan sulfate
(GAG component of the glycocalyx) [13] backbone with multiple selectin-binding peptides attached.
EC-SEAL variants differing in type and number of peptides attached were investigated to determine
highest binding affinities to inflamed ECs and assess ability to prevent platelet binding along the EC
surface. Results indicated effective molecule binding to inflamed ECs and subsequent prevention of
platelet binding and activation, as well as suppression of thrombus formation in a murine model of
DVT, highlighting the possibility of EC-SEAL as a therapeutic to treat EC dysfunction.
2. Results
2.1. Selectin Expression
To measure levels of selectin expression on SMCs and ECs under various conditions, antibodies
designed to target E-selectin were utilized. ECs were stimulated with 5 or 25 ng/mL tumor necrosis
factor (TNF)-α or control (unstimulated) media, and SMCs were stimulated with only control
(unstimulated) media. While all cultures showed selectin expression compared to the background (No
Cells), there was no difference in expression between cultures that contained TNF-α stimulated and
control media (Figure 1). Since antibodies are likely cross-reactive with P-selectin, these data suggest
SMCs, which have been shown to express P-selectin [35,36] but not E-selectin [37], also exhibited
selectin expression. Both lower and higher concentrations of TNF-α (Supplementary Figure S1) and
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other proinflammatory cytokines (interleukin (IL)-1β, IL-6, lipopolysaccharide (LPS)) at varying
concentrations (10–100 ng/mL) (Supplementary Figure S2) were tested in an attempt to upregulate
selectin expression compared to unstimulated ECs. All proinflammatory stimuli failed to show any
upregulation in selectin expression, indicating that EC cultures likely exhibited a basal upregulation
of selectin receptors. Additionally, ECs were unable to form fully intact monolayers despite a lack of
proinflammatory stimuli present, as indicated by their permeability to fluorescently-labeled dextran
(Supplementary Figure S3). This lack of cell–cell junctions under normal conditions is another
indication that the cultured ECs were likely in a constitutively activated state.
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biotinylated peptides on each molecule bound to the surface. None of the EC-SEAL variants 
displayed a significant difference in binding to unstimulated ECs and ECs stimulated with TNF-α. 
Variants containing the peptide IEL showed the highest binding affinity to ECs. n = 3; p < 0.05. 
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control. As indicated in Figure 3, DS-IEL4, DS-IEL7 and DS-IEL10 had the highest number of 
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EC-SEAL variant. Absorbance was measured using a streptavidin-HRP assay to quantify biotinylated
peptides on each molecule bound to the surface. None of the EC-SEAL variants displayed a significant
difference in binding to unstimulated ECs and ECs stimulated with TNF-α. Variants containing the
peptide IEL showed the highest binding affinity to ECs. n = 3; p < 0.05.
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subsequent activation was quantified. We first investigated DS-IEL10 because, based on its increased
level of binding to endothelial cells (Figure 3), we expected that it would best inhibit platelet binding
as compared to the other variants we examined. DS-IEL30 was included to verify that the IEL peptide
would not enhance platelet binding to the activated endothelium due to its interaction with the
P-selectin receptor that is present on platelets. Levels of NAP-2 and PF-4, released from platelets during
activation [18,20,38], were used as platelet activation markers to compare various treatment conditions.
Surprisingly, treating ECs with DS-IEL10 prior to platelet rich plasma (PRP) incubation had no effect
on NAP-2 and PF-4 release as compared to the control (No Treatment), regardless of concentration of
DS-IEL10 applied (Figure 4). However, treating with 30 µM DS-IEL30 showed a significant decrease in
NAP-2 and PF-4 levels when compared to the control and all other treatment groups.
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Figure 4. Impact of DS-IEL10 and DS-IEL30 on platelet activation markers NAP-2 and PF-4. ECs were
stimulated with 5 ng/mL TNF-α and treated with 3–30 µM EC-SEAL variants or control (No Treatment).
PRP was added and NAP-2 and PF-4 levels in the collected PRP were recorded using sandwich ELISAs.
DS-IEL30 showed the greatest reduction in platelet activation. * represents a significant difference from
the control (No Treatment); # represents a significant difference when compared to all other treatment
groups. n = 3; p < 0.05.
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Next, various concentrations of DS-IEL30 were tested to determine an effective dose. As shown
in Figure 5, DS-IEL30 decreases platelet activation markers at 10 µM compared to the control (No
Treatment), however, treating with 30 µM DS-IEL30 results in a greater decrease in both NAP-2 and
PF-4 compared to the control and all other treatment groups. The individual components of DS-IEL30,
DS only (30 µM) and free IEL peptide (0.9 mM), were also tested at concentrations equivalent to 30 µM
DS-IEL30. While both components decreased platelet activation markers compared to the control,
neither did so as effectively as 30 µM DS-IEL30.
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Figure 5. Dose-dependent response of DS-IEL30 on platelet activation. ECs were stimulated with
5 ng/mL TNF-α and treated with 3–30 µM DS-IEL30 or control (No Treatment). PRP was added and
NAP-2 and PF-4 levels in the collected PRP were recorded using sandwich ELISAs. DS-IEL30 at 30 µM
proved to be the most effective dose to reduce platelet activation. * represents a significant difference
from the control (No Treatment); # represents a significant difference when compared to all other
treatment groups. n = 2; p < 0.05.
In addition to reducing platelet activation, DS-IEL30 was also shown to prevent platelet binding
to ECs (Figure 6). Labeled with membrane bound C llTrackers, platelets (red) were added to ECs
(green) with a d without prior 30 µM DS-IEL30 treatm nt. Treated EC cultures (Figure 6B) displayed
a decrease in over ll platelet binding, particularly directly on ECs, compared to untreated cultures
(Figure 6A). In addition, the l mited number of platelets that did bind to cultures treated with DS-IEL30
appeared to bind i areas not covered by ECs, indicating that DS-IEL30 was preferentially targeting
ECs (and not the underlying tissue culture plastic) and subsequently preventing platelet binding
and activation.
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Figure 6. Platelets binding to ECs in the presence of EC-SEAL. ECs (green) were stimulated with
5 ng/mL TNF-α and treated with: control media (A); or 30 µM DS-IEL30 (B). Platelets (red) were
isolated from human whole blood and incubated on ECs. Cultures treated with DS-IEL30 showed
less platelet binding, particularly on EC surfaces. The 10× images were acquired using a fluorescent
microscope. Scale bar = 250 µm. n = 3.
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2.4. EC-SEAL Binding (Selectin Protein)
To confirm that the observed interactions between EC-SEAL variants and cells were through a
selectin binding process, the ability of DS-IEL30 to preferentially bind to selectin protein was studied.
Increasing concentrations of human recombinant E-selectin were coated on a high bind plate and 1%
bovine serum albumin (BSA) was added to eliminate nonspecific binding. A single concentration
of DS-IEL30 (3 µM) was incubated and the amount bound to the surface was quantified (Figure 7).
Initially, DS-IEL30 binding increases with increased concentrations of E-selectin. Then, at 50 µg/mL
E-selectin, DS-IEL30 binding falls off slightly, but is overcome with further increases in E-selectin
concentration (100 µg/mL).
A similar trend is observed when the binding of antibodies (primary mouse monoclonal
anti-E-selectin IgG2a with secondary goat anti-mouse IgG HRP-conjugated) are quantified under
the same conditions (Figure 8). There is also an initial increase in antibody binding with increased
concentrations of E-selectin. Then, at 10 µg/mL E-selectin, antibody binding falls off significantly, but
is also overcome with increasing concentrations of E-selectin (25–100 µg/mL).
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2.5. DVT Mouse Model
To assess the effects of DS-IEL30 in vivo, a study utilizing a mouse model of DVT was conducted.
Partial ligation of the inferior vena cava (IVC) was performed and tail vein injections of saline
(n = 6), 200 IU/kg heparin (n = 6), or 30 µM DS-IEL30 (n = 4) were administered. Ultrasound images
were obtained at 6 h post-ligation for each mouse (Figure 9). The thrombus volume (expressed
as mean ± standard error of the mean) was 12.3 ± 1.6 mm3 for saline, 5.0 ± 2.2 mm3 for heparin,
and 4.3 ± 2.2 mm3 for DS-IEL30. The mean thrombus percentage (defined as thrombus volume/total
IVC volume between the ligation suture and iliac bifurcation) was 63% ± 5% for saline, 26% ± 11% for
heparin, and 26% ± 11% for DS-IEL30 (Figure 10). Both heparin and DS-IEL30 significantly decreased
thrombus percentage compared to the saline controls (p < 0.05).
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Figure 10. Thrombus percentage in DVT mouse model. Ultrasound images were utilized to calculate
thrombus percentage by dividing thrombus volume by total IVC volume between the partial ligation
suture and iliac bifurcation. Both heparin (n = 6) and EC-SEAL (n = 4) decreased thrombus percentage
compared to saline controls (n = 6). * represents a significant difference from the control group (Saline).
p < 0.05.
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2.6. Clotting Time (aPTT)
Although heparin and EC-SEAL (DS-IEL30) showed statistically equivalent outcomes with respect
to thrombus percentage in the DVT mouse model, it is believed these effects are achieved through
different mechanisms. Therefore, clotting times (activated partial thromboplastin time (aPTT)) were
obtained for various concentrations of heparin and EC-SEAL (Figure 11). It should be noted that
the highest concentration of both heparin and EC-SEAL depicted in Figure 11 were equivalent to
the doses administered to mice in vivo. Heparin displayed a substantial effect, causing a nearly
four-fold increase in aPTT at the highest dose compared to saline controls. Comparatively, EC-SEAL
exhibited a relatively small effect on aPTT (e.g., 23% increase at the highest concentration compared to
saline controls).
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dysfunction, this process can lead to co plications in a yriad of disease states including T,
atherosclerosis, diabetes, chronic kidney disease and sepsis [3,4,6,8,39]. asking these selectins ith
antibodies or peptides to prevent platelet binding presents a possible avenue of treat ent [28–30].
e sought to develop and test ultiple variants of a derived, selectin-binding anti-adhesive
coating (ter ed E -SE L) utilizing selectin-binding peptides to bind to an infla ed endothelial
surface. e de onstrate the ability to successfully synthesize variants ranging fro 2 to 30 peptides
per der atan sulfate olecule that bind to E-selectin and cells expressing selectins, and prevent
platelet binding and activation in a dose-dependent anner. dditionally, e present evidence that
the lead variant reduces thro bus size in vivo hile exhibiting ini al effects on clotting ti e.
In order to exa ine the binding of EC-SE L variants to vascular cells, e first established that
selectin as present on the cell surfaces. As shown in Figure 1 and Supplementary Figures S1 and S2,
ECs (which express both E and P-selectin) did not increase selectin levels following TNF-α stimulation
or any other proinflammatory sti ulants used. Although not anticipated because it has been shown
previously that adding TNF-α to human aortic ECs leads to an increase in E-selectin expression 3–6 h
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after stimulation [40–42], there is also evidence that many different factors including number of cell
passages, seeding density, certain growth factors present in media, and even the culture substrate can
lead to increased basal levels of adhesion molecules on cultured ECs [43–46]. It is also possible that
the rinsing and manipulation of the live ECs throughout the experiments contributed to the observed
basal selectin expression. The presence of selectins on the EC surface in the unstimulated cultures,
the lack of response to multiple proinflammatory cytokines (TNF-α, LPS, IL-1β and IL-6), and the
inability to form intact monolayers (Supplementary Figure S3), all suggest that the EC cultures were
in a constitutively activated state. SMCs, known to express P-selectin [35,36], but not E-selectin [37],
demonstrated P-selectin cross-reactivity with the anti-E-selectin antibody.
The selectin-expressing cells were then used to test and compare EC-SEAL variant binding. Both
the type and number of peptides attached to the DS backbone had a significant impact on binding
affinity (Figures 2 and 3). There was no difference in binding to unstimulated ECs or ECs stimulated
with TNF-α for any EC-SEAL variant, which is consistent with the selectin expression data discussed
previously. Although nearly all variants had a higher binding affinity to ECs, they also adhered to
SMCs, presumably through P-selectin. Prior studies on IDL and IEL peptides indeed indicated binding
to both E and P-selectin [31]. QIT was previously shown to have a significantly higher preference for
E-selectin over P-selectin [47], but in our hands the binding observed in the DS-QITx variants was
primarily due to nonspecific interactions as indicated by the (relatively) high level of binding with no
cells present compared to both SMCs and ECs (Figure 2). IEL was selected as the peptide to examine
further due to its increased binding to ECs and reduced nonspecific interactions when no cells were
present. This is consistent with a previous study that showed IEL had a higher binding affinity to
E-selectin expressing bacteria than IDL [31]. Importantly, all DS-IELx variants showed increased levels
of binding compared to only DS, which as a native glycocalyx component will interact with the EC
surface, indicating the benefit of the selectin-binding peptides. The apparent ability to bind to both E
and P-selectin is also viewed as advantageous as it may allow for more complete coverage of: (1) ECs
expressing both E and P-selectin; and (2) SMCs expressing P-selectin should they become exposed
following EC injury or denudation.
DS-IEL10 was originally chosen for platelet binding and activation testing given that it possessed
the greatest number of selectin-binding peptides among the highest binding group of DS-IELx variants
(Figure 3.) However, using NAP-2 and PF-4 as platelet activation markers, DS-IEL10 did not reduce
platelet activation at any treatment concentration compared to untreated controls (Figure 4). DS-IEL30
was also studied because the high density of selectin-binding peptide per backbone presented the
possibility that some peptide would not be bound to the endothelial cell surface and might in fact
bind to P-selectin on platelets and increase platelet binding. Importantly, there was no evidence for
platelet-peptide interactions in these studies; in fact, DS-IEL30 showed a dose-dependent response in
reducing platelet activation compared to untreated controls (Figure 5). Additionally, 30 µM DS-IEL30
proved to be an extremely effective dose even when compared to equivalent amounts of its individual
components (30 µM DS Only and 0.9 mM Free IEL Peptide). We believe that the apparent discrepancy
between the binding studies (where DS-IEL10 was believed to be best) and platelet activation results
(where DS-IEL30 was most effective) lies in how the binding was quantified. Since each DS backbone
has one biotinylated peptide, the streptavidin-HRP assay will quantify each DS molecule attached
regardless of the number of selectin-binding peptides bound to the surface. Therefore, despite DS-IEL10
showing a slightly more than two-fold increase in number of molecules bound compared to DS-IEL30,
there are three times the number of selectin-binding peptides on each molecule of DS-IEL30, resulting
in a higher number of peptides available to bind to the cell surface and block interaction with platelets.
Furthermore, increasing the number of peptides per molecule appeared to decrease nonspecific
interactions (Figures 2 and 3) and therefore, more of the molecules likely reached and bound to their
targeted site. This suggests that despite fewer molecules present, the higher local peptide density of
DS-IEL30 supports more efficient binding to the EC surface to prevent platelet binding and activation.
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The ability of DS-IEL30 to preferentially bind to recombinant human E-selectin over BSA
was observed by incubating a single concentration of DS-IEL30 on plates coated with increasing
concentrations of E-selectin. DS-IEL30 binding increased with initial increases in E-selectin
concentration, but dropped off at a certain point, only to increase again upon a further increase
in E-selectin concentration (Figure 7). Interestingly, anti-E-selectin antibodies exhibited a similar
binding trend, although at different concentrations of E-selectin (Figure 8). We hypothesize that these
binding characteristics are due to a potential selectin conformational change that is dependent upon
concentration of both receptor (E-selectin) and ligand (DS-IEL30 or antibody) and their respective
binding affinities. Ligand binding itself is known to cause conformational changes at the binding
site [48,49], including that of E-selectin [50,51]. It is also possible that the concentration of E-selectin
protein coated on the plate’s surface influences the orientation in which the protein adsorbs and
therefore, the exposure (or lack thereof) of ligand binding sites. Given that DS-IEL30 and anti-E-selectin
antibody may have different binding sites and affinities to E-selectin, it is not surprising that the drop
off and subsequent rise in binding occur at different concentrations of plated E-selectin protein.
Given the vast number of vascular disease states associated with endothelial dysfunction, animal
models in this area are wide-ranging. The utilization of mouse models has proven to be an extremely
useful tool allowing for the study of underlying mechanisms and initial screenings of therapeutics [52].
Thus, we employed a mouse model of deep vein thrombosis mediated endothelial dysfunction to
observe the anti-thrombotic effects of EC-SEAL in vivo. This inferior vena cava (IVC) partial ligation
model provides valuable information regarding vessel wall-blood interactions during thrombus
formation and has been used previously to evaluate therapeutic agents [52,53]. Study results, obtained
via ultrasound imaging, indicate that DS-IEL30 significantly decreases thrombus formation at six
hours following IVC partial ligation (Figure 10) and highlight the potential for DS-IEL30 to act
locally following systemic administration. It is believed that these therapeutic effects are due to
DS-IEL30 binding to the vessel wall and subsequently preventing platelet binding and not through
direct anticoagulant properties. Dermatan sulfate from porcine origin (which is the type used for
EC-SEAL synthesis) has been shown to have very minimal anticoagulant properties depending on
the concentration [54]. By measuring aPTT of whole blood that had been incubated with varying
concentrations of both heparin and DS-IEL30, we have confirmed the minimal effect of DS-IEL30 on
clotting time (Figure 11). Therefore, EC-SEAL has the potential to be utilized as a treatment for DVT
without the negative side effects of current standard of care anticoagulant therapies such as heparin.
Since DS-IEL30 proved to be the most effective EC-SEAL variant and no variants were synthesized
with greater than 30 peptides per DS molecule, it is possible that further increases to the number of
peptides per molecule may be beneficial. Previous work has shown, however, that excessive oxidation
of GAGs can lead to chain scission [55,56], so a balance between number of selectin-binding peptides
and DS backbone integrity will need to be considered. It is also possible that targeting additional
EC adhesion molecules, such as ICAM-1 or VCAM-1, may further increase binding and therapeutic
effect. Future studies on DS-IEL30 and any additional EC-SEAL variants can focus on prevention of
leukocyte binding and subsequent diapedesis. Additional experiments further assessing the specificity
of EC-SEAL binding as well as observing the binding characteristics of EC-SEAL over time and under
flow conditions to account for shear forces would be valuable.
4. Materials and Methods
4.1. GAG Dervied, Selectin Targeting Anti-Adhesive Coating (EC-SEAL) Synthesis
The synthesis of the GAG derived, selectin targeting anti-adhesive coating variants (Scheme 1)
was performed at room temperature as follows: vicinal diol groups on dermatan sulfate (DS, MWavg
46,275 Da, Celsus Laboratories, Cincinnati, OH, USA) were oxidized to aldehydes using sodium
meta-periodate (Thermo Fisher Scientific, Waltham, MA, USA) in 0.1 M acetate buffer. The ratio
of DS to sodium meta-periodate varied depending on the desired degree of oxidation. Following
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oxidation, the modified DS was isolated via size exclusion chromatography (SEC) (AKTA Purifier
FPLC, GE Healthcare). An excess of N-[β-maleimidopropionic acid] hydrazide, trifluoroacetic acid salt
(BMPH, Thermo Fisher Scientific), was then conjugated via the hydrazide to the DS aldehyde groups
in 1× phosphate buffered saline (PBS, 1.05 mM KH2PO4, 155.17 mM NaCl, 2.97 Na2HPO4-7H2O;
pH 7.4, Thermo Fisher Scientific) to form DS-BMPHx. Unbound BMPH was removed via SEC and
quantified by calculating the area under the peak to determine the average number (x) of BMPH
molecules bound to each DS backbone. Next, biotinylated peptide was added at a 1:1 molar ratio of
DS:biotinylated peptide in 1× PBS to conjugate an average of one biotinylated peptide per molecule
of DS, and then an excess of one of three selectin-binding peptides (Genscript, Piscataway, NJ, USA)
was conjugated via the cysteine thiol to the maleimide groups on DS-BMPHx in 1× PBS. The three
peptide sequences used were as follows: IDLMQARGC (IDL) [31], IELLQARGC (IEL) [31,32,34,57],
and QITWAQLWNMMKGC (QIT) [47]. After the peptide reaction was complete, semicarbazide
hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was added directly to the solution to reduce any
unreacted aldehyde groups. Subsequent SEC isolation and lyophilization resulted in the purified
sixteen variants containing from one to thirty peptides per DS backbone of DS-BMPHx-Peptidex, biotin
(hereby simply referred to in the form of DS-Peptidex, ex: DS-IEL20).
Pharmaceuticals 2017, 10, 36 12 of 19 
 
groups in 1× phosphate buffered saline (PBS, 1.05 mM KH2PO4, 155.17 mM NaCl, 2.97 
Na2HPO4-7H2O; pH 7.4, Thermo Fisher Scientific) to form DS-BMPHx. Unbound BMPH was 
removed via SEC and quantified by calculating the area under the peak to determine the average 
number (x) of BMPH molecules bound to each DS backbone. Next, biotinylated peptide was added 
at a 1:1 molar ratio of DS:biotinylated peptide in 1× PBS to conjugate an average of one biotinylated 
peptide per molecule of DS, and then an excess of one of three selectin-binding peptides (Genscript, 
Piscataw y, NJ, USA) was conjugated via the cysteine thiol to the maleimide groups on DS-BMPHx 
in 1× PBS. The three peptid  sequences used were as follows: IDLMQARGC (IDL) [31], IELLQARGC 
(IEL) [31,32,34,57], and QITWAQLWNMMKGC (QIT) [47]. After the peptide reaction was complete, 
semicarbazide hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was added directly to the 
solution to reduce any unreacted aldehyde groups. Subsequent SEC isolation and lyop ilization 
resulted in the purified sixteen variants containing from one to thirty peptides per DS backbone of 
DS-BMPHx-Peptidex, biotin (hereby simply referred to in the form of DS-Peptidex, ex: DS-IEL20). 
 
Schematic 1. GAG-derived, selectin targeting anti-adhesive coating (EC-SEAL) synthesis. 
4.2. Cell Cultures 
Human aortic endothelial cells (ECs, Thermo Fisher Scientific) were cultured in Medium 200 (M 
200, Thermo Fisher Scientific) with low serum growth supplement (LSGS, Thermo Fisher Scientific). 
Human coronary artery smooth muscle cells (SMCs, Thermo Fisher Scientific) were cultured in 
Medium 231 (M 231, Thermo Fisher Scientific) with smooth muscle growth supplement (SMGS, 
Thermo Fisher Scientific). Cells were maintained at 37 °C and 5% CO2. Unless otherwise noted, 
passage 3–7 cells were seeded at a density of 1 × 105 cells/cm2 on tissue culture polystyrene and 
allowed to adhere for 24 h prior to any stimulation or treatment. 
4.3. Selectin Expression 
Monolayers of SMCs and ECs were seeded separately on Biocoat Collagen I Cellware 96-well 
plates (Corning, Corning, NY, USA). ECs were stimulated for four hours with 0.05–50 ng/mL tumor 
necrosis factor-α (TNF-α, Thermo Fisher Scientific), 10–100 ng/mL interleukin-1β (IL-1β, PeproTech, 
Rocky Hill, NJ, USA), 10–100 ng/mL interleukin-6 (IL-6, PeproTech), 10–100 ng/mL 
lipopolysaccharide (LPS, Sigma-Aldrich) or control (unstimulated) media. SMCs were cultured with 
only control (unstimulated) media. To block nonspecific binding, cells were treated with 1% bovine 
serum albumin (BSA, Sigma-Aldrich) in 0.05 M tris-buffered saline (TBS, 0.138 M NaCl, 0.0027 M 
KCl; pH 8.0, Sigma-Aldrich) for 30 min at room temperature with shaking. Primary rabbit polyclonal 
anti-E-selectin IgG (Santa Cruz Biotechnology, Dallas, TX, USA) or mouse monoclonal 
anti-E-selectin IgG2a (Santa Cruz Biotechnology) antibody was added (1:50 dilution of initial 200 
μg/mL in 1% BSA in TBS) for one hour at 4 °C with shaking. Cells were rinsed three times with 1% 
BSA in TBS and secondary donkey anti-rabbit IgG HRP-conjugated (Thermo Fisher Scientific) or 
goat anti-mouse IgG HRP-conjugated (Thermo Fisher Scientific) antibody was added (1:1000 
dilution of initial 0.5 mg/mL in 1% BSA in TBS) for 30 min at room temperature with shaking. Cells 
were rinsed three times with 1% BSA in TBS and colorimetric change was induced with 1:1 
hydrogen peroxide: tetramethylbenzidine (R&D Systems, Minneapolis, MN, USA). Following 20 
min of incubation with shaking, 2N sulfuric acid was added to cease the reaction and absorbance 
was measured at 450 nm and 540 nm using a SpectraMax M5 plate reader (Molecular Devices, 
Scheme 1. GA -derived, selectin targeting anti-adhesive coating ( - t esis.
4.2. Cell Cultures
Human aortic endothelial cells (ECs, Thermo Fisher Scientific) were cultured in Medium 200
(M 200, Thermo Fisher Scientific) with low serum growth supplement (LSGS, Thermo Fisher Scientific).
Human coronary artery smooth muscle cells (SMCs, Thermo Fisher Scientific) were cultured in Medium
231 (M 231, Thermo Fisher Scientific) with smooth muscle growth supplement (SMGS, Thermo Fisher
Scientific). Cells were maintained at 37 ◦C and 5% CO2. Unless otherwise noted, passage 3–7 cells
were seeded at a density of 1 × 105 cells/cm2 on tissue culture polystyrene and allowed to adhere for
24 h prior to any stimulation or treatment.
4.3. Selectin Expression
Monolayers of SMCs and ECs were seeded separately on Biocoat Collagen I Cellware 96-well
plates (Corning, Corning, NY, USA). ECs were stimulated for four hours with 0.05–50 ng/mL
tumor necrosis factor-α (TNF-α, Thermo Fisher Scientific), 10–100 ng/mL interleukin-1β (IL-1β,
PeproTech, Rocky Hill, NJ, USA), 10–100 ng/mL interleukin-6 (IL-6, PeproTech), 10–100 ng/mL
lipopolysaccharide (LPS, Sigma-Aldrich) or control (unstimulated) media. SMCs were cultured with
only control (unstimulated) media. To block nonspecific bin ing, cells were treated with 1% bovine
serum albumin (BSA, Sigma-Aldrich) in 0.05 M tris-buffered saline (TBS, 0.138 M NaCl, 0.0027 M
KCl; pH 8.0, Sigma-Aldrich) for 30 min at room temperature with shaking. P imary rabbit p lyclonal
anti-E-selectin IgG (Santa Cruz Biotechnology, Dall s, TX, USA) or mouse monoclonal anti-E-selectin
IgG2a (Santa Cruz Biotechnol gy) antibody was added (1:50 dilution of initial 200 µg/ L in 1% BSA
in TBS) for one hour at 4 ◦C with shaking. Cells were rinsed thre times with 1% BSA i TBS and
secondary donkey anti-rabbit IgG HRP-conjugated (Thermo Fisher Scientific) or goat anti-mouse IgG
HRP-conjugated (Ther o Fisher Scientific) antibody was added (1:1000 dilution of initial 0.5 mg/mL
in 1% BSA in TBS) for 30 min at room temperature with shaking. Cells were rinsed three times with 1%
BSA in TBS and colorimetric change was induced with 1:1 hydrogen peroxide: tetramethylbenzidine
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(R&D Systems, Minneapolis, MN, USA). Following 20 min of incubation with shaking, 2N sulfuric
acid was added to cease the reaction and absorbance was measured at 450 nm and 540 nm using a
SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA). For each individual well,
540 nm was subtracted from 450 nm to obtain final absorbance reading.
4.4. EC Monolayer Permeability
ECs were seeded in control (unstimulated) media on tissue culture treated Transwell polyester
membrane inserts with 3.0 µm pores on a 24-well plate (Corning) and cultured for 48 h to form
monolayers. Cell culture media in both the upper and lower chambers was then changed with fresh,
unstimulated media, and Rhodamine B isothiocyanate (RITC)-dextran (Sigma-Aldrich) was added to
obtain a final concentration of 3 mg/mL in the upper chamber. The monolayers were incubated at 37 ◦C
and 5% CO2 for four hours, then the media in the lower chamber was removed and fluorescence was
read using an M5 plate reader (Ex: 520 nm; Em: 590 nm).
4.5. EC-SEAL Binding to Cells
Monolayers of SMCs and ECs were seeded separately on Biocoat Collagen I Cellware 96-well
plates or CellBIND surface 96-well plates (Corning). ECs were stimulated for four hours with 5 ng/mL
TNF-α or control (unstimulated) media, and SMCs were treated with only control (unstimulated)
media. Nonspecific binding was blocked using 1% BSA in TBS with 150 mM CaCl2 for 20 min at
room temperature with shaking. Cells were then treated with EC-SEAL variants (3 µM in 1% BSA in
TBS with 150 mM CaCl2) for one hour at 37 ◦C and 5% CO2. After rinsing three times with 1% BSA
in TBS with 150 mM CaCl2, streptavidin-HRP (R&D Systems) was diluted 1:200 in 1% BSA in TBS
with 150 mM CaCl2 and added for 20 min at room temperature with shaking. After three more rinses
in TBS with 150 mM CaCl2, a 1:1 hydrogen peroxide: tetramethylbenzidine solution was added to
induce colorimetric change. After 20 min of incubation with shaking, 2N sulfuric acid was used to
stop the reaction and an M5 plate reader was utilized to measure absorbance at 450 nm and 540 nm as
described above.
4.6. Platelet Activation
EC monolayers were seeded on Biocoat Collagen I Cellware 96-well plates and stimulated with
5 ng/mL TNF-α for four hours. One-percent BSA in TBS with 150 mM CaCl2 was added for 15 min
at room temperature to decrease nonspecific binding. ECs were then treated with 3–30 µM EC-SEAL
variants for 1 h at 37 ◦C and 5% CO2. Whole blood was obtained from healthy volunteers in collection
vials containing sodium citrate and centrifuged for 20 min at 200× g and 25 ◦C. Platelet rich plasma
(PRP) was isolated and after EC-SEAL treatments, ECs were rinsed three times with TBS with 150 mM
CaCl2 and 100 µL of PRP was added to each well. After 1 h of incubation at room temperature, 45 µL of
PRP was then removed and added to tubes containing 5 µL of ETP (107 mM Ethylenediaminetetraacetic
acid, disodium salt (EDTA, Promega, Madison, WI, USA), 12 mM Theophylline (Sigma-Aldrich) and
2.8 mM Prostaglandin E1 (Enzo Life Sciences, Farmingdale, NY, USA) in water). Samples were then
centrifuged for 30 min at 2000× g and 4 ◦C and supernatant was collected and stored at −80 ◦C for
use in subsequent assays.
4.7. NAP-2 and PF-4 ELISA
To quantify platelet activation, neutrophil activating peptide-2 (NAP-2) and platelet factor-4 (PF-4)
levels in PRP collected from platelet activation experiments were measured utilizing sandwich ELISAs.
Mouse monoclonal anti-hNAP-2 IgG and anti-hPF-4 IgG2B capture antibodies (R&D Systems) were
coated on 96-well EIA/RIA high binding plates (Corning) at 2 µg/mL in 1× phosphate buffered saline
(PBS) and incubated at 4 ◦C overnight. After rinsing three times with 1× PBS + 0.05% Tween and
blocking with 1% BSA in 1× PBS for 1 h at room temperature with shaking, previously collected PRP
samples were thawed, diluted 1:10,000 in 1% BSA in 1× PBS and added for 2 h at room temperature
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with shaking. Samples were removed, wells were triple rinsed with 1× PBS + 0.05% Tween and
biotinylated polyclonal goat anti-hNAP-2 IgG and anti-hPF-4 IgG detection antibodies (R&D Systems)
were added at 0.2 µg/mL in 1× PBS for 2 h at room temperature with shaking. After three rinses in 1×
PBS + 0.05% Tween, streptavidin-HRP (diluted 1:200 in 1% BSA in 1× PBS) was added and detected as
described above.
4.8. Platelet Binding
EC monolayers were seeded on CellBIND surface 96-well plates and stimulated with 5 ng/mL
TNF-α for four hours to create a proinflammatory environment. CellTracker Green CMFDA
(5-chloromethylfluorescein diacetate) (Thermo Fisher Scientific) was dissolved in dimethyl sulfoxide
(DMSO), diluted in EC media and added to ECs for 20 min at 37 ◦C and 5% CO2. Cells were then
rinsed three times in TBS with 150 mM CaCl2 and 1% BSA in TBS with 150 mM CaCl2 was added
to ECs for 10 min at room temperature to decrease nonspecific binding. ECs were then treated with
30 µM EC-SEAL variants for 1 h at 37 ◦C and 5% CO2. PRP was isolated from human whole blood
as described above and labeled with CellTracker Orange CMRA (Thermo Fisher Scientific) (which
was previously dissolved in DMSO) for 25 min at 37 ◦C and 5% CO2. Platelets were then pelleted via
centrifugation for 10 min at 900× g and 25 ◦C, supernatant was removed and remaining platelets were
suspended in EC media. Following EC-SEAL treatments and rinsing three times in TBS with 150 mM
CaCl2, labeled platelets in EC media were added to ECs for 1 h at 37 ◦C and 5% CO2. After incubation,
media was removed and the cells were rinsed in TBS with 150 mM CaCl2 and then fixed with 3%
paraformaldehyde for 20 min at room temperature. Three final rinses with TBS with 150 mM CaCl2
were performed and cells were imaged using a Leica DMI6000 B microscope with EL6000 external light
source (Leica Microsystems, Wetzler, Germany) and CoolSNAP HQ2 camera (Photometrics, Tucson,
AZ, USA). Leica application suite (LAS) AF6000 software (Leica Microsystems) was utilized for image
acquisition. Excitation/emission spectra used were 460–500 nm/512–542 nm for ECs (green) and
540–552 nm/580–620 nm for platelets (orange). Contrast and brightness editing of acquired images
was accomplished using the program ImageJ (National Institutes of Health, Bethesda, MD, USA) and
identical settings were applied to all images.
4.9. EC-SEAL Binding (Selectin Protein)
Recombinant human E-selectin (PeproTech) was dissolved in water and added to a 96-well
EIA/RIA high binding plate at 0.1–100 µg/mL. Following overnight incubation at 4 ◦C, the plate was
rinsed three times with TBS with 150 mM CaCl2 and blocked with 1% BSA in TBS with 150 mM CaCl2
for 1 h at room temperature with shaking. The plate was then rinsed three more times with TBS with
150 mM CaCl2. In experiments observing EC-SEAL binding, 3 µM EC-SEAL (in 1%BSA in TBS with
150 mM CaCl2) was added for 1 h at room temperature with shaking. Following three rinses with
TBS with 150 mM CaCl2, streptavidin-HRP (1:200 in 1% BSA in TBS with 150 mM CaCl2) was added
for 20 min at room temperature with shaking. For experiments observing antibody binding, primary
mouse monoclonal anti-E-selectin IgG2a antibody was added (1:50 dilution of initial 200 µg/mL in 1%
BSA in TBS) for two hours at room temperature with shaking. Following three rinses with TBS with
150 mM CaCl2, secondary goat anti-mouse IgG HRP-conjugated antibody was added (1:1000 dilution
of initial 0.5 mg/mL in 1% BSA in TBS) for 1 h at room temperature with shaking. HRP activity was
detected as described above.
4.10. DVT Mouse Model
Ten-week-old C57BL/6 male mice (average weight: 26.4 g) were utilized in a model of
surgically-induced deep vein thrombosis (DVT). All animals used in this study were obtained from
Jackson Laboratory (Bar Harbor, ME) and fed standard chow diet. A well-established model of DVT
caused by a significant inferior vena cava (IVC) flow restriction was utilized following a protocol
(1505001247) approved by the institutional animal care and use committee at Purdue University. Mice
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were anesthetized using 1%–3% isoflurane and oxygen at a flow rate of 225 mL/min [58]; toe pinch was
be used to determine sufficient anesthetic induction. Buprenorphine (0.03 mg/mL) was subcutaneously
injected near the incision site at 0.05 mg/kg for pain management. Using aseptic technique, a small
incision was made in the abdomen and the entrails were carefully exteriorized onto a sterile saline
soaked gauze pad to prevent desiccation. The skin and organs were further retracted to fully expose
the IVC, its branching vessels, and the infrarenal aorta. The aorta was then carefully separated from
the IVC directly below the left renal vein. In an attempt to ligate all side and back branching vessels of
the IVC, 6-0 black silk-braided sutures and a low power cautery pen (Bovie Medical, Purchase, NY,
USA) were used, respectively. To achieve flow restriction, the proximal region of the IVC below the left
renal vein was partially ligated by placing a 30-guage needle adjacent to the IVC and then tying a 6-0
black silk-braided suture around both the IVC and needle. The needle was then removed, resulting
in an approximate 90% reduction in flow through the vessel. The muscle and skin layer were closed
using 5-0 polypropylene sutures. A syringe with a 30-gauge needle was utilized to inject 100 µL of
30 µM EC-SEAL (n = 4), 200 IU/kg heparin (n = 6), or saline (n = 6) via tail vein. Tail vein injections
were made approximately 10 min post-partial ligation of the IVC.
4.11. Ultrasound Imaging
Mice were anesthetized using 2%–3% isoflurane in 1.5 L/min oxygen. Cardiac and respiration
rates were noninvasively monitored using gold-plated stage electrodes as part of the Vevo imaging
station (FUJIFILM VisualSonics Inc., Toronto, ON, Canada). The mice were placed in a supine
position on heated animal stage and the temperature was monitored using a rectal probe such that
animals remained near 37◦C. Depilatory cream was applied to remove hair on the abdomen prior
to imaging, and warm ultrasound gel was applied on the skin to the entire abdomen just below
the xiphoid process. IVC images were obtained using a Vevo2100 ultrasound imaging system with
MS550D (40 MHz center frequency) and MS700 (50 MHz center frequency) transducers (FUJIFILM
VisualSonics). The transducers were locked in the adjustable arm of the Vevo integrated rail system
(FUJIFILM VisualSonics) for consistent image collection. In order to prevent distortion of the IVC,
minimal pressure was applied to the abdomen to maintain original diameter of the vessel. The walls
of the IVC were visualized with both long and short axes views. The angle of the stage was adjusted
to optimize the view of the IVC and to minimize artifacts due to air and gas. Long and short axis
B-mode images of the IVC were acquired at baseline (pre-operation) and at 6 h post-ligation of the IVC.
Color Doppler images were used to assess blood flow through the IVC and branching vessels, and 3D
scans of sequential slices were used to obtain vessel volumes as described previously [59,60] . Suture
placement and the bifurcation of the IVC were used as landmarks to ensure consistent measurements
between mice.
4.12. Ultrasound Image Analysis
All vessel measurements were made by the same ultrasonographer using Vevo LAB software
(FUJIFILM VisualSonics). Thrombus length and volume and vessel volume were calculated using
both the long axis and short axis ultrasound images. To determine the location of the thrombus,
Color Doppler flow and B-mode images were utilized to visualize blood flow. The thrombus was
also visualized as a hyperechoic region within the vessel lumen. Thrombus length was determined
from the suture (point of IVC partial ligation) to the farthest point of thrombus and was calculated
using an average of five measurements per image. The length of the thrombus in the 3D scans was
compared to the length of thrombus in the long axis B-mode to ensure agreement. Thrombus volume
was calculated by lofting together individual 2D segmentations from the first hyperechoic region in
the lumen to the suture (where the lumen signal changed from hyperechoic to hypoechoic). Total
IVC vessel volume was obtained using these same volumetric images and was measured from the
suture to the IVC bifurcation. Percentage of IVC occlusion was obtained by determining the amount of
thrombus volume within the total volume of the vessel.
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4.13. Clotting Time (aPTT)
Activated partial thromboplastin time (aPTT) was measured using a Hemochron® Response
(Accriva Diagnostics, San Diego, CA, USA) with associated reagents. The protocol was run according
to manufacturer’s instructions. Briefly, whole blood was obtained from healthy volunteers in sodium
citrate collection vials and 2 mL was added to the Hemochron® aPTT (citrated blood) test tube.
One hundred microliters of saline, heparin or EC-SEAL was then added (final concentrations:
3.75–15 µg/mL heparin; 13–128 µg/mL EC-SEAL), and the test tube was shaken vigorously ten
times from end-to-end. The test tube was then placed into the Hemochron® Response device and
clotting time was recorded at completion.
4.14. Statistics
Unless otherwise noted, all experiments were performed in triplicate or quadruplicate (n ≥ 2)
and results are presented as mean ± standard deviation. Statistical analysis was performed using
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). All results were analyzed
using ANOVA with post-hoc Tukey test. Statistical significance threshold was set at p < 0.05.
5. Conclusions
Here, we present the development of a novel GAG derived, selectin targeting anti-adhesive
coating (termed EC-SEAL) consisting of a dermatan sulfate backbone with multiple selectin-binding
peptides designed to treat EC dysfunction. We demonstrated the ability of different EC-SEAL variants
to successfully bind to selectin-expressing vascular ECs and SMCs. The most effective variants were
examined further and DS-IEL30 was shown to preferentially bind to selectin protein and inhibit platelet
binding and activation on inflamed EC surfaces. Additionally, DS-IEL30 reduced thrombus size in vivo
in a DVT mouse model while exhibiting a minimal effect on clotting time. Thus, by binding to
and pacifying the surface of inflamed endothelium, EC-SEAL has the potential to be utilized as a
therapeutic in multiple diseases associated with endothelial dysfunction.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/10/2/36/s1,
Figure S1: Selectin expression on ECs when stimulated with varying concentrations of TNF-α, Figure S2: Selectin
expression on ECs when stimulated with varying concentrations of IL-1β, IL-6 and LPS, Figure S3: EC monolayer
permeability in unstimulated conditions.
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